Compare Ascendis Pharma A/S (ASND) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while First Trust NASDAQ 100 Technology Index Fund trades at $321.04. Which is the better fit depends on your goals.
| ASND | QTEC | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $335.74 |
52-Week Low | $163.32 | $207.03 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $321.04, down 0.2% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF provides equal-weighted exposure to leading technology firms, tracking the Nasdaq-100 Technology Sector Index. Recent news highlights its role in broad tech exposure, with a 52-week high noted at $248.89 in April 2026, though current levels are significantly higher, indicating strong momentum.
Outlook remains positive given the ETF's focus on high-growth tech sectors, but risks include market volatility and sector concentration. Analyst sentiment is generally supportive, with institutional interest in tech diversification. Investors should weigh the ETF's performance against broader market trends and potential regulatory shifts affecting technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
